Back to Search
Start Over
Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT).
- Source :
-
Acta dermato-venereologica [Acta Derm Venereol] 2024 Nov 27; Vol. 104, pp. adv40946. Date of Electronic Publication: 2024 Nov 27. - Publication Year :
- 2024
-
Abstract
- Real-world data on the effectiveness and safety of tildrakizumab, an interleukin 23p19 inhibitor, in Switzerland is limited. The objectives of this analysis were to assess the effectiveness and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis in Switzerland. Twenty-eight adults from the Swiss Dermatology Network for Targeted Therapies registry (SDNTT), who were on tildrakizumab treatment and had at least 3 months' follow-up, were enrolled in this prospective, multicentre study. No missing data imputation was performed. The median Psoriasis Area and Severity Index (PASI) decreased from 9.5 at baseline to 2.1 and 0.3 (both p < 0.001) after 3 and 18 months, respectively, of tildrakizumab treatment. After 3 months, 76.9%/30.8% patients reached an absolute PASI < 3/ < 1. These rates increased to 85.7%/57.1% after 18 months of treatment. The proportions of patients achieving PASI 90/100 responses were 47.8%/30.4% at month 6 and 42.9%/14.3% at month 18. A significant improvement in quality of life up to 18 months of follow-up was observed as measured by the Dermatology Life Quality Index. There were no treatment discontinuations due to adverse events. This real-world registry provides robust evidence supporting the long-term effectiveness and favourable safety profile of tildrakizumab in treating patients with moderate-to-severe psoriasis.
- Subjects :
- Humans
Male
Female
Switzerland
Middle Aged
Adult
Prospective Studies
Treatment Outcome
Time Factors
Dermatologic Agents therapeutic use
Dermatologic Agents adverse effects
Aged
Quality of Life
Interleukin-23 Subunit p19 antagonists & inhibitors
Psoriasis drug therapy
Registries
Antibodies, Monoclonal, Humanized therapeutic use
Antibodies, Monoclonal, Humanized adverse effects
Severity of Illness Index
Subjects
Details
- Language :
- English
- ISSN :
- 1651-2057
- Volume :
- 104
- Database :
- MEDLINE
- Journal :
- Acta dermato-venereologica
- Publication Type :
- Academic Journal
- Accession number :
- 39601368
- Full Text :
- https://doi.org/10.2340/actadv.v104.40946